Spondyloarthritis & psoriatic arthritis
Four-year secukinumab treatment outcomes in European real-world patients with axial spondyloarthritis and psoriatic arthritis
Authors' conclusion
This large European real-world study demonstrates that 4-year secukinumab retention rates were approximately 50% in both axSpA and PsA. b/tsDMARD naïve patients had higher retention, remission and LDA rates than patients with prior b/tsDMARD exposure.
Study context
- Population
- Patients with axial spondyloarthritis (axSpA) and psoriatic arthritis (PsA) initiating secukinumab, pooled from 13 European registries13 European registries
- Participants
- 767 vs 975
- Exposure
- Secukinumab retention and remission/low disease activity (LDA) by number of previous b/tsDMARDs (0/1/≥2), in axSpA and PsA
- axSpAn = 767
- PsAn = 975
- Outcome
- Secukinumab retention rates and proportions achieving remission and LDA
- Follow-up
- 24 and 48 months
Methodological detailspooled European registries, real-world, 13 European registries, stratified by number of previous b/tsDMARDs (0/1/≥2), Kaplan-Meier and Cox regression, logistic regression
- Pooled European registries
- Real-world
- 13 European registries
- Stratified by number of previous b/tsDMARDs (0/1/≥2)
- Kaplan-Meier and Cox regression
- Logistic regression
Main finding
As reported in the abstract
Secukinumab retention rate (24-/48-month)
axSpA
61%/51%
PsA
64%/49%
Observational data: associations, not effects.
Further findings
Withdrawal from secukinumab by prior b/tsDMARDs
- Higher risk of withdrawal vs b/tsDMARD naïve for ≥2 prior b/tsDMARDs in axSpA and PsA, and 1 prior b/tsDMARD in axSpA
Remission and LDA rates by prior b/tsDMARDs · 24 months
- Remission and LDA rates generally numerically higher in b/tsDMARD naïve patients
- After adjustment, significantly higher remission and LDA rates in b/tsDMARD naïve vs ≥2 prior b/tsDMARDs at 24 months in axSpA and PsA
- Adjusted for confounders
Original publication
Four-year secukinumab treatment outcomes in European real-world patients with axial spondyloarthritis and psoriatic arthritis. Joint Bone Spine. Published 26 November 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →